The Gut Microbial Metabolite Trimethylamine N-Oxide is Linked to Specific Complications of Systemic Sclerosis

References

• Denton CP, Khanna D. Systemic sclerosis. Lancet. 2017;390(10103):1685–1699. doi:10.1016/s0140-6736(17)30933-9
   PubMed Web of Science ®Google Scholar
• Bobeica C, Niculet E, Craescu M, et al. CREST syndrome in systemic sclerosis patients - is dystrophic calcinosis a key element to a positive diagnosis? J Inflamm Res. 2022;15:3387–3394. doi:10.2147/JIR.S361667
   PubMed Web of Science ®Google Scholar
• Bernero E, Sulli A, Ferrari G, et al. Prospective capillaroscopy-based study on transition from primary to secondary Raynaud’s phenomenon: preliminary results. Reumatismo. 2013;65(4):186–191. doi:10.4081/reumatismo.2013.186
   PubMedGoogle Scholar
• Pawlik KK, Bohdziewicz A, Chrabaszcz M, et al. Biomarkers of disease activity in systemic sclerosis. Wiad Lek. 2020;73(10):2300–2305. doi:10.36740/WLek202010137
   PubMedGoogle Scholar
• Utsunomiya A, Oyama N, Hasegawa M. Potential biomarkers in systemic sclerosis: a literature review and update. J Clin Med. 2020;9(11):3388. doi:10.3390/jcm9113388
   PubMed Web of Science ®Google Scholar
• Smith V, Pizzorni C, Riccieri V, et al. Stabilization of microcirculation in patients with early systemic sclerosis with diffuse skin involvement following rituximab treatment: an open-label study. J Rheumatol. 2016;43(5):995–996. doi:10.3899/jrheum.151018
   PubMed Web of Science ®Google Scholar
• Cheng H, Yu Z, Yan CL, Yang HD, Gao C, Wen HY. Long-term efficacy and low adverse events of methylprednisolone pulses combined to low-dose glucocorticoids for systemic sclerosis: a retrospective clinical study of 10 years’ follow-up. J Inflamm Res. 2022;15:4421–4433. doi:10.2147/JIR.S373387
   PubMed Web of Science ®Google Scholar
• Patrone V, Puglisi E, Cardinali M, et al. Gut microbiota profile in systemic sclerosis patients with and without clinical evidence of gastrointestinal involvement. Sci Rep. 2017;7(1):14874. doi:10.1038/s41598-017-14889-6
   PubMed Web of Science ®Google Scholar
• Volkmann ER, Chang YL, Barroso N, et al. Association of systemic sclerosis with a unique colonic microbial consortium. Arthritis Rheumatol. 2016;68(6):1483–1492. doi:10.1002/art.39572
   PubMed Web of Science ®Google Scholar
• Volkmann ER, Hoffmann-Vold AM, Chang YL, et al. Systemic sclerosis is associated with specific alterations in gastrointestinal microbiota in two independent cohorts. BMJ Open Gastroenterol. 2017;4(1):e000134. doi:10.1136/bmjgast-2017-000134
   PubMed Web of Science ®Google Scholar
• Andreasson K, Lee SM, Lagishetty V, et al. Disease features and gastrointestinal microbial composition in patients with systemic sclerosis from two independent cohorts. ACR Open Rheumatol. 2022;4(5):417–425. doi:10.1002/acr2.11387
   PubMedGoogle Scholar
• Andréasson K, Alrawi Z, Persson A, Jönsson G, Marsal J. Intestinal dysbiosis is common in systemic sclerosis and associated with gastrointestinal and extraintestinal features of disease. Arthritis Res Ther. 2016;18(1):278. doi:10.1186/s13075-016-1182-z
   PubMedGoogle Scholar
• Frech TM, Khanna D, Maranian P, Frech EJ, Sawitzke AD, Murtaugh MA. Probiotics for the treatment of systemic sclerosis-associated gastrointestinal bloating/ distention. Clin Exp Rheumatol. 2011;29(2 Suppl 65):S22–S25.
   PubMed Web of Science ®Google Scholar
• Low AHL, Teng GG, Pettersson S, et al. A double-blind randomized placebo-controlled trial of probiotics in systemic sclerosis associated gastrointestinal disease. Semin Arthritis Rheum. 2019;49(3):411–419. doi:10.1016/j.semarthrit.2019.05.006
   PubMed Web of Science ®Google Scholar
• Fretheim H, Chung BK, Didriksen H, et al. Fecal microbiota transplantation in systemic sclerosis: a double-blind, placebo-controlled randomized pilot trial. PLoS One. 2020;15(5):e0232739. doi:10.1371/journal.pone.0232739
   PubMed Web of Science ®Google Scholar
• Hoffmann-Vold A-M, Fretheim H, Chung BK, et al. OP0327 Fecal microbiota transplantation in systemic sclerosis: a double-blind, placebo-controlled randomized pilot trial. Ann Rheum Dis. 2019;78(Suppl2):246–247. doi:10.1136/annrheumdis-2019-eular.4684
   Google Scholar
• Sakkas LI, Simopoulou T, Daoussis D, Liossis SN, Potamianos S. Intestinal involvement in systemic sclerosis: a clinical review. Dig Dis Sci. 2018;63(4):834–844. doi:10.1007/s10620-018-4977-8
   PubMed Web of Science ®Google Scholar
• Caserta L, de Magistris L, Secondulfo M, et al. Assessment of intestinal permeability and orocecal transit time in patients with systemic sclerosis: analysis of relationships with epidemiologic and clinical parameters. Rheumatol Int. 2003;23(5):226–230. doi:10.1007/s00296-003-0286-3
   PubMed Web of Science ®Google Scholar
• Catanoso M, Lo Gullo R, Giofré MR, et al. Gastro-intestinal permeability is increased in patients with limited systemic sclerosis. Scand J Rheumatol. 2001;30(2):77–81. doi:10.1080/03009740151095303
   PubMed Web of Science ®Google Scholar
• Taguchi K, Fukami K, Elias BC, Brooks CR. Dysbiosis-related advanced glycation endproducts and trimethylamine N-oxide in chronic kidney disease. Toxins. 2021;13(5):361. doi:10.3390/toxins13050361
   PubMed Web of Science ®Google Scholar
• Chen YY, Chen DQ, Chen L, et al. Microbiome-metabolome reveals the contribution of gut-kidney axis on kidney disease. J Transl Med. 2019;17(1):5. doi:10.1186/s12967-018-1756-4
   PubMedGoogle Scholar
• Janeiro MH, Ramírez MJ, Milagro FI, Martínez JA, Solas M. Implication of trimethylamine N-oxide (TMAO) in disease: potential biomarker or new therapeutic target. Nutrients. 2018;10(10):1398. doi:10.3390/nu10101398
   PubMed Web of Science ®Google Scholar
• Zhou Z, Jin H, Ju H, Sun M, Chen H, Li L. Circulating trimethylamine-N-oxide and risk of all-cause and cardiovascular mortality in patients with chronic kidney disease: a systematic review and meta-analysis. Front Med. 2022;9:828343. doi:10.3389/fmed.2022.828343
   Web of Science ®Google Scholar
• Zhuang R, Ge X, Han L, et al. Gut microbe-generated metabolite trimethylamine N-oxide and the risk of diabetes: a systematic review and dose-response meta-analysis. Obes Rev. 2019;20(6):883–894. doi:10.1111/obr.12843
   PubMed Web of Science ®Google Scholar
• Ufnal M, Zadlo A, Ostaszewski R. TMAO: a small molecule of great expectations. Nutrition. 2015;31(11–12):1317–1323. doi:10.1016/j.nut.2015.05.006
   PubMed Web of Science ®Google Scholar
• Tang WH, Wang Z, Fan Y, et al. Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis. J Am Coll Cardiol. 2014;64(18):1908–1914. doi:10.1016/j.jacc.2014.02.617
   PubMed Web of Science ®Google Scholar
• Qi J, You T, Li J, et al. Circulating trimethylamine N-oxide and the risk of cardiovascular diseases: a systematic review and meta-analysis of 11 prospective cohort studies. J Cell Mol Med. 2018;22(1):185–194. doi:10.1111/jcmm.13307
   PubMed Web of Science ®Google Scholar
• Zhu W, Gregory JC, Org E, et al. Gut microbial metabolite TMAO enhances platelet hyperreactivity and thrombosis risk. Cell. 2016;165(1):111–124. doi:10.1016/j.cell.2016.02.011
   PubMed Web of Science ®Google Scholar
• Tang WH, Wang Z, Kennedy DJ, et al. Gut microbiota-dependent trimethylamine N-oxide (TMAO) pathway contributes to both development of renal insufficiency and mortality risk in chronic kidney disease. Circ Res. 2015;116(3):448–455. doi:10.1161/circresaha.116.305360
   PubMed Web of Science ®Google Scholar
• Coras R, Kavanaugh A, Boyd T, et al. Choline metabolite, trimethylamine N-oxide (TMAO), is associated with inflammation in psoriatic arthritis. Clin Exp Rheumatol. 2019;37(3):481–484.
   PubMed Web of Science ®Google Scholar
• Chan MM, Yang X, Wang H, Saaoud F, Sun Y, Fong D. The microbial metabolite trimethylamine N-oxide links vascular dysfunctions and the autoimmune disease rheumatoid arthritis. Nutrients. 2019;11(8):1821. doi:10.3390/nu11081821
   PubMed Web of Science ®Google Scholar
• Kim SJ, Bale S, Verma P, et al. Gut microbe-derived metabolite trimethylamine N-oxide activates PERK to drive fibrogenic mesenchymal differentiation. iScience. 2022;25(7):104669. doi:10.1016/j.isci.2022.104669
   PubMed Web of Science ®Google Scholar
• Cutolo M, Sulli A, Smith V. Assessing microvascular changes in systemic sclerosis diagnosis and management. Nat Rev Rheumatol. 2010;6(10):578–587. doi:10.1038/nrrheum.2010.104
   PubMed Web of Science ®Google Scholar
• Ufnal M, Jazwiec R, Dadlez M, Drapala A, Sikora M, Skrzypecki J. Trimethylamine-N-oxide: a carnitine-derived metabolite that prolongs the hypertensive effect of angiotensin II in rats. Can J Cardiol. 2014;30(12):1700–1705. doi:10.1016/j.cjca.2014.09.010
   PubMed Web of Science ®Google Scholar
• Sikora M, Kiss N, Stec A, et al. Trimethylamine N-oxide, a gut microbiota-derived metabolite, is associated with cardiovascular risk in psoriasis: a cross-sectional pilot study. Dermatol Ther. 2021;11(4):1277–1289. doi:10.1007/s13555-021-00547-3
   Web of Science ®Google Scholar
• Fu BC, Hullar MAJ, Randolph TW, et al. Associations of plasma trimethylamine N-oxide, choline, carnitine, and betaine with inflammatory and cardiometabolic risk biomarkers and the fecal microbiome in the Multiethnic Cohort Adiposity Phenotype Study. Am J Clin Nutr. 2020;111(6):1226–1234. doi:10.1093/ajcn/nqaa015
   PubMed Web of Science ®Google Scholar
• Lohia S, Vlahou A, Zoidakis J. Microbiome in chronic kidney disease (CKD): an omics perspective. Toxins. 2022;14(3):176. doi:10.3390/toxins14030176
   PubMed Web of Science ®Google Scholar
• Wu P, Zhu T, Tan Z, Chen S, Fang Z. Role of gut microbiota in pulmonary arterial hypertension. Front Cell Infect Microbiol. 2022;12:812303. doi:10.3389/fcimb.2022.812303
   PubMed Web of Science ®Google Scholar
• Wang Z, Cai Z, Ferrari MW, et al. The correlation between gut microbiota and serum metabolomic in elderly patients with chronic heart failure. Mediators Inflamm. 2021;2021:5587428. doi:10.1155/2021/5587428
   PubMed Web of Science ®Google Scholar
• Zanin-Silva DC, Santana-Goncalves M, Kawashima-Vasconcelos MY, Oliveira MC. Management of endothelial dysfunction in systemic sclerosis: current and developing strategies. Front Med. 2021;8:788250. doi:10.3389/fmed.2021.788250
   PubMed Web of Science ®Google Scholar
• Brunt VE, Gioscia-Ryan RA, Casso AG, et al. Trimethylamine-N-oxide promotes age-related vascular oxidative stress and endothelial dysfunction in mice and healthy humans. Hypertension. 2020;76(1):101–112. doi:10.1161/HYPERTENSIONAHA.120.14759
   PubMed Web of Science ®Google Scholar
• Querio G, Antoniotti S, Geddo F, Levi R, Gallo MP. Trimethylamine N-oxide (TMAO) impairs purinergic induced intracellular calcium increase and nitric oxide release in endothelial cells. Int J Mol Sci. 2022;23(7):3982. doi:10.3390/ijms23073982
   PubMed Web of Science ®Google Scholar
• Kim S, Rigatto K, Gazzana MB, et al. Altered gut microbiome profile in patients with pulmonary arterial hypertension. Hypertension. 2020;75(4):1063–1071. doi:10.1161/hypertensionaha.119.14294
   PubMed Web of Science ®Google Scholar
• Huang Y, Lin F, Tang R, et al. Gut microbial metabolite trimethylamine N-oxide aggravates pulmonary hypertension. Am J Respir Cell Mol Biol. 2022;66(4):452–460. doi:10.1165/rcmb.2021-0414OC
   PubMed Web of Science ®Google Scholar
• Yang Y, Zeng Q, Gao J, et al. High-circulating gut microbiota-dependent metabolite trimethylamine N-oxide is associated with poor prognosis in pulmonary arterial hypertension. Eur Heart J Open. 2022;2(5):oeac021. doi:10.1093/ehjopen/oeac021
   PubMedGoogle Scholar
• Li X, Geng J, Zhao J, et al. Trimethylamine N-oxide exacerbates cardiac fibrosis via activating the NLRP3 inflammasome. Front Physiol. 2019;10:866. doi:10.3389/fphys.2019.00866
   PubMed Web of Science ®Google Scholar
• Sikora M, Stec A, Chrabaszcz M, et al. Clinical implications of intestinal barrier damage in psoriasis. J Inflamm Res. 2021;14:237–243. doi:10.2147/JIR.S292544
   PubMed Web of Science ®Google Scholar
• Nanto-Hara F, Kanemitsu Y, Fukuda S, et al. The guanylate cyclase C agonist linaclotide ameliorates the gut-cardio-renal axis in an adenine-induced mouse model of chronic kidney disease. Nephrol Dial Transplant. 2020;35(2):250–264. doi:10.1093/ndt/gfz126
   PubMed Web of Science ®Google Scholar
• Simo C, Garcia-Canas V. Dietary bioactive ingredients to modulate the gut microbiota-derived metabolite TMAO. New opportunities for functional food development. Food Funct. 2020;11(8):6745–6776. doi:10.1039/d0fo01237h
   PubMed Web of Science ®Google Scholar
• Coutinho-Wolino KS, de FC, de Oliveira Leal V, Mafra D, Stockler-Pinto MB. Can diet modulate trimethylamine N-oxide (TMAO) production? What do we know so far? Eur J Nutr. 2021;60(7):3567–3584. doi:10.1007/s00394-021-02491-6
   PubMed Web of Science ®Google Scholar